Revelation Biosciences, a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease, went public via a SPAC merger with Petra Acquisition, a special purpose acquisition company, in a $128m deal. "Revelation Biosciences represents an opportunity to dramatically reduce the impact and severity respiratory infections have on our lives. This transaction will provide James and the proven leadership team at Revelation the capital necessary to continue innovating in the world of innate immune system therapeutics and diagnostics – the first step towards a healthier future," Andreas Typaldos, Petra CEO and Chairman.